Can a common antibiotic beat MRSA in kids? a trial puts TMP-SMX to the test

NCT ID NCT06982105

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial compares two oral antibiotics—trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin—to see which works better for children with invasive MRSA infections, such as bone, joint, or deep tissue infections. About 100 children aged 60 days to 18 years will take one of the drugs and be monitored for treatment success and side effects over six months. The goal is to determine if TMP-SMX is a safe and effective alternative to clindamycin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
trimethoprim-sulfamethoxazole (TMP-SMX) compared to clindamycin, both antibiotics
What this could lead to
If TMP-SMX proves as effective as clindamycin, it could offer a safe, alternative oral antibiotic for children with serious MRSA infections.
What could go wrong
This is a Phase 4 trial with 100 children, so results may not apply to all cases. TMP-SMX may cause side effects or be less effective than clindamycin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL ADENITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Riley Hospital for Children

    RECRUITING

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.